H Kadara1, M Choi2,3, J Zhang4, E R Parra5, J Rodriguez-Canales5, S G Gaffney6, Z Zhao6, C Behrens7, J Fujimoto5, C Chow5, Y Yoo8, N Kalhor, C Moran, D Rimm9, S Swisher10, D L Gibbons7, J Heymach7, E Kaftan9, J P Townsend6, T J Lynch9, J Schlessinger9, J Lee4, R P Lifton2,11, I I Wistuba5, R S Herbst9. 1. Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American University of Beirut, Beirut, Lebanon. 2. Department of Genetics, Howard Hughes Medical Institute, Maryland, USA. 3. Department of Biomedical Sciences, Seoul National University, Seoul, Republic of Korea. 4. Department of Biostatistics and Computational Biology, Indiana University Melvin and Bren Simon Cancer Center , Indianapolis , Indiana , USA. 5. Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston. 6. Department of Ecology and Evolutionary Biology, Yale University, New Haven. 7. Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. 8. Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea. 9. Yale Comprehensive Cancer Center, Yale School of Medicine, Yale University, New Haven. 10. Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston. 11. Yale Center for Genome Analysis, Yale School of Medicine, Yale University, New Haven, USA.
Abstract
Background: Lung adenocarcinomas (LUADs) lead to the majority of deaths attributable to lung cancer. We performed whole-exome sequencing (WES) and immune profiling analyses of a unique set of clinically annotated early-stage LUADs to better understand the pathogenesis of this disease and identify clinically relevant molecular markers. Methods: We performed WES of 108 paired stage I-III LUADs and normal lung tissues using the Illumina HiSeq 2000 platform. Ten immune markers (PD-L1, PD-1, CD3, CD4, CD8, CD45ro, CD57, CD68, FOXP3 and Granzyme B) were profiled by imaging-based immunohistochemistry (IHC) in a subset of LUADs (n = 92). Associations among mutations, immune markers and clinicopathological variables were analyzed using ANOVA and Fisher's exact test. Cox proportional hazards regression models were used for multivariate analysis of clinical outcome. Results: LUADs in this cohort exhibited an average of 243 coding mutations. We identified 28 genes with significant enrichment for mutation. SETD2-mutated LUADs exhibited relatively poor recurrence- free survival (RFS) and mutations in STK11 and ATM were associated with poor RFS among KRAS-mutant tumors. EGFR, KEAP1 and PIK3CA mutations were predictive of poor response to adjuvant therapy. Immune marker analysis revealed that LUADs in smokers and with relatively high mutation burdens exhibited increased levels of immune markers. Analysis of immunophenotypes revealed that LUADs with STK11 mutations exhibited relatively low levels of infiltrating CD4+/CD8+ T-cells indicative of a muted immune response. Tumoral PD-L1 was significantly elevated in TP53 mutant LUADs whereas PIK3CA mutant LUADs exhibited markedly down-regulated PD-L1 expression. LUADs with TP53 or KEAP1 mutations displayed relatively increased CD57 and Granzyme B levels indicative of augmented natural killer (NK) cell infiltration. Conclusion(s): Our study highlights molecular and immune phenotypes that warrant further analysis for their roles in clinical outcomes and personalized immune-based therapy of LUAD.
Background: Lung adenocarcinomas (LUADs) lead to the majority of deaths attributable to lung cancer. We performed whole-exome sequencing (WES) and immune profiling analyses of a unique set of clinically annotated early-stage LUADs to better understand the pathogenesis of this disease and identify clinically relevant molecular markers. Methods: We performed WES of 108 paired stage I-III LUADs and normal lung tissues using the Illumina HiSeq 2000 platform. Ten immune markers (PD-L1, PD-1, CD3, CD4, CD8, CD45ro, CD57, CD68, FOXP3 and Granzyme B) were profiled by imaging-based immunohistochemistry (IHC) in a subset of LUADs (n = 92). Associations among mutations, immune markers and clinicopathological variables were analyzed using ANOVA and Fisher's exact test. Cox proportional hazards regression models were used for multivariate analysis of clinical outcome. Results: LUADs in this cohort exhibited an average of 243 coding mutations. We identified 28 genes with significant enrichment for mutation. SETD2-mutated LUADs exhibited relatively poor recurrence- free survival (RFS) and mutations in STK11 and ATM were associated with poor RFS among KRAS-mutant tumors. EGFR, KEAP1 and PIK3CA mutations were predictive of poor response to adjuvant therapy. Immune marker analysis revealed that LUADs in smokers and with relatively high mutation burdens exhibited increased levels of immune markers. Analysis of immunophenotypes revealed that LUADs with STK11 mutations exhibited relatively low levels of infiltrating CD4+/CD8+ T-cells indicative of a muted immune response. Tumoral PD-L1 was significantly elevated in TP53 mutant LUADs whereas PIK3CA mutant LUADs exhibited markedly down-regulated PD-L1 expression. LUADs with TP53 or KEAP1 mutations displayed relatively increased CD57 and Granzyme B levels indicative of augmented natural killer (NK) cell infiltration. Conclusion(s): Our study highlights molecular and immune phenotypes that warrant further analysis for their roles in clinical outcomes and personalized immune-based therapy of LUAD.
Authors: Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi Journal: Nature Date: 2014-11-27 Impact factor: 49.962
Authors: Murim Choi; Ute I Scholl; Peng Yue; Peyman Björklund; Bixiao Zhao; Carol Nelson-Williams; Weizhen Ji; Yoonsang Cho; Aniruddh Patel; Clara J Men; Elias Lolis; Max V Wisgerhof; David S Geller; Shrikant Mane; Per Hellman; Gunnar Westin; Göran Åkerström; Wenhui Wang; Tobias Carling; Richard P Lifton Journal: Science Date: 2011-02-11 Impact factor: 47.728
Authors: Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan Journal: Science Date: 2015-03-12 Impact factor: 47.728
Authors: Siming Zhao; Murim Choi; John D Overton; Stefania Bellone; Dana M Roque; Emiliano Cocco; Federica Guzzo; Diana P English; Joyce Varughese; Sara Gasparrini; Ileana Bortolomai; Natalia Buza; Pei Hui; Maysa Abu-Khalaf; Antonella Ravaggi; Eliana Bignotti; Elisabetta Bandiera; Chiara Romani; Paola Todeschini; Renata Tassi; Laura Zanotti; Luisa Carrara; Sergio Pecorelli; Dan-Arin Silasi; Elena Ratner; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Amy L Stiegler; Shrikant Mane; Titus J Boggon; Joseph Schlessinger; Richard P Lifton; Alessandro D Santin Journal: Proc Natl Acad Sci U S A Date: 2013-01-28 Impact factor: 11.205
Authors: Marcin Imielinski; Alice H Berger; Peter S Hammerman; Bryan Hernandez; Trevor J Pugh; Eran Hodis; Jeonghee Cho; James Suh; Marzia Capelletti; Andrey Sivachenko; Carrie Sougnez; Daniel Auclair; Michael S Lawrence; Petar Stojanov; Kristian Cibulskis; Kyusam Choi; Luc de Waal; Tanaz Sharifnia; Angela Brooks; Heidi Greulich; Shantanu Banerji; Thomas Zander; Danila Seidel; Frauke Leenders; Sascha Ansén; Corinna Ludwig; Walburga Engel-Riedel; Erich Stoelben; Jürgen Wolf; Chandra Goparju; Kristin Thompson; Wendy Winckler; David Kwiatkowski; Bruce E Johnson; Pasi A Jänne; Vincent A Miller; William Pao; William D Travis; Harvey I Pass; Stacey B Gabriel; Eric S Lander; Roman K Thomas; Levi A Garraway; Gad Getz; Matthew Meyerson Journal: Cell Date: 2012-09-14 Impact factor: 41.582
Authors: Ariella B Hanker; Adam D Pfefferle; Justin M Balko; María Gabriela Kuba; Christian D Young; Violeta Sánchez; Cammie R Sutton; Hailing Cheng; Charles M Perou; Jean J Zhao; Rebecca S Cook; Carlos L Arteaga Journal: Proc Natl Acad Sci U S A Date: 2013-08-12 Impact factor: 11.205
Authors: Eun Mi Je; Min Gwak; Hyerim Oh; Mi Ryoung Choi; Youn Jin Choi; Sug Hyung Lee; Nam Jin Yoo Journal: Pathology Date: 2013-12 Impact factor: 5.306
Authors: Kurt A Schalper; Jason Brown; Daniel Carvajal-Hausdorf; Joseph McLaughlin; Vamsidhar Velcheti; Konstantinos N Syrigos; Roy S Herbst; David L Rimm Journal: J Natl Cancer Inst Date: 2015-02-03 Impact factor: 11.816
Authors: Kyle G Mitchell; Edwin R Parra; David B Nelson; Jiexin Zhang; Ignacio I Wistuba; Junya Fujimoto; Jack A Roth; Mara B Antonoff Journal: J Thorac Cardiovasc Surg Date: 2019-05-17 Impact factor: 5.209
Authors: Tina Cascone; Jodi A McKenzie; Rina M Mbofung; Simone Punt; Zhe Wang; Chunyu Xu; Leila J Williams; Zhiqiang Wang; Christopher A Bristow; Alessandro Carugo; Michael D Peoples; Lerong Li; Tatiana Karpinets; Lu Huang; Shruti Malu; Caitlin Creasy; Sara E Leahey; Jiong Chen; Yuan Chen; Helen Pelicano; Chantale Bernatchez; Y N Vashisht Gopal; Timothy P Heffernan; Jianhua Hu; Jing Wang; Rodabe N Amaria; Levi A Garraway; Peng Huang; Peiying Yang; Ignacio I Wistuba; Scott E Woodman; Jason Roszik; R Eric Davis; Michael A Davies; John V Heymach; Patrick Hwu; Weiyi Peng Journal: Cell Metab Date: 2018-04-05 Impact factor: 27.287
Authors: Smruthy Sivakumar; F Anthony San Lucas; Tina L McDowell; Wenhua Lang; Li Xu; Junya Fujimoto; Jianjun Zhang; P Andrew Futreal; Junya Fukuoka; Yasushi Yatabe; Steven M Dubinett; Avrum E Spira; Jerry Fowler; Ernest T Hawk; Ignacio I Wistuba; Paul Scheet; Humam Kadara Journal: Cancer Res Date: 2017-09-26 Impact factor: 12.701
Authors: Junya Fujimoto; Sayuri Nunomura-Nakamura; Yihua Liu; Wenhua Lang; Tina McDowell; Yasminka Jakubek; Dalia Ezzeddine; Joshua Kapere Ochieng; Jason Petersen; Gareth Davies; Junya Fukuoka; Ignacio I Wistuba; Erik Ehli; Jerry Fowler; Paul Scheet; Humam Kadara Journal: Int J Cancer Date: 2017-07-17 Impact factor: 7.396
Authors: Jacob Kantrowitz; Ansam Sinjab; Li Xu; Tina L McDowell; Smruthy Sivakumar; Wenhua Lang; Sayuri Nunomura-Nakamura; Junya Fukuoka; Georges Nemer; Nadine Darwiche; Hassan Chami; Arafat Tfayli; Ignacio I Wistuba; Paul Scheet; Junya Fujimoto; Avrum E Spira; Humam Kadara Journal: Cancer Prev Res (Phila) Date: 2018-01-30